Drug General Information (ID: DDIVGUQ819)
Drug Name			Talimogene laherparepvec		Drug Info		Brexucabtagene autoleucel		Drug Info
Drug Type		Vaccine				Autologous cell transplant
Therapeutic Class		Anticancer Agents				Antineoplastics

Mechanism of Talimogene laherparepvec-Brexucabtagene autoleucel Interaction (Severity Level: Major)
Antagonize the effect of vaccine/toxoid Click to Show/Hide Mechanism Graph
Drug Name		Talimogene laherparepvec				Brexucabtagene autoleucel
Mechanism		Immunomodulatory infective agent				Immunosuppressive effects
Key Mechanism Factor 1
		Factor Name		Vaccine/toxoid
		Factor Description		The beneficial effects of the vaccine/toxinoid may be reduced, leading to a diminished or suboptimal immune response.
Mechanism Description		Antagonize the effect of Talimogene laherparepvec when combined with Brexucabtagene autoleucel

Recommended Action
Management		Talimogene laherparepvec should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy. Treatment with talimogene laherparepvec may need to be deferred until after such therapy is discontinued and the patient's immune system has sufficiently recovered.

References
1	Product Information. Imlygic (talimogene laherparepvec). Amgen USA, Thousand Oaks, CA.